Advertisement
Organisation › Details
SV Life Sciences Advisers LLP
SV Life Sciences is a leading, international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the Firm closed its first dedicated life sciences fund in 1994. SVLS’ team of 32 professionals is organized according to experience and specialization into three practice areas: Biotechnology/Biopharmaceuticals, Medical Devices/Instrumentation, and Healthcare Services/Healthcare IT. These individuals’ diverse and complementary skill sets and experiences enable SVLS to tailor an investment team for almost any life science business. Typically, SVLS recruits operating executives, called Venture Partners, who have distinguished careers in the life sciences fields and can bring extensive operating expertise to the SVLS portfolio of investments. They assist in sourcing, building and exiting investments successfully. In some cases, these individuals are promoted to serve as Partners and/or Managing Partners within the Firm. SVLS employs a close symbiosis between operating and financial professionals which has led to significant success over five investment funds. SVLS has offices in Boston, London and San Francisco. *
Start | 2005-08-02 existent | |
End | 2017-04-10 renamed | |
Group | SV Health Investors (Group) | |
Today | SV Health Investors LLP | |
Successor | SV Health Investors LLP | |
Industry | fund, biotech / life sciences | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Street | 71 Kingsway | |
City | WX2B London | |
Tel | +44-20-7421-7070 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2018-10-30 |
Advertisement
More documents for SV Health Investors (Group)
- [1] Eyebiotech Ldt.. (2/22/22). "Press Release: EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies". London & New York, NY....
- [2] LoQus23 Therapeutics Ltd.. (11/23/21). "Press Release: LoQus23 Therapeutics Exits Stealth with £11.5 Million Seed Financing from the Dementia Discovery Fund and Novartis Venture Fund". Cambridge....
- [3] Mestag Therapeutics Ltd.. (4/20/21). "Press Release: Mestag Therapeutics Launches with Seed Financing of $11 Million to Develop Therapeutics Targeting Activated Fibroblast Populations across Inflammatory Disease and Cancer". Cambridge....
- [4] Cellinta Ltd.. (9/15/20). "Press Release: Launch of Cellinta and Appointment of Dr Soraya Bekkali as CEO". London....
- [5] Ervaxx Ltd.. (11/6/19). "Press Release: Ervaxx Launches to Pioneer the Use of Dark Antigens for the Development of Off-the-Shelf Cancer Vaccines and T-cell Receptor-based Immunotherapies". London....
- [6] Cancer Research UK. (7/2/19). "Press Release: Cancer Research UK Forms Collaboration with SV Health Investors to Accelerate Development of Cancer Medicines"....
- [7] Sitryx Therapeutics Ltd.. (10/8/18). "Press Release: New Biopharmaceutical Company Sitryx Launches with $30 Million Fundraising to Develop Disease Modifying Therapeutics in Immunometabolism". Oxford....
- [8] Immuneering Corporation. (6/18/18). "Press Release: The Dementia Discovery Fund and Immuneering Announce a Research Collaboration to Identify Novel Drug Targets and Drug Candidates for Alzheimer's Disease". Cambridge, MA & London....
- [9] EBD Group. (10/13/17). "Press Release: BIO-Europe 2017 to Bring 3,800 Life Science Leaders to Berlin November 6–8". Carlsbad, CA & Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top